GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

PBYI · Dec 31, 2023

PUMA BIOTECHNOLOGY, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001437749-24-006121General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

43.29% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.06% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

11.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

3.00% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

73.40% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

13.85% · CORE · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.35% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building

Jun 30, 20230/5 normalizedLevel 3 Sep 30, 20230/7 normalizedLevel 3 Dec 31, 20230/7 normalizedLevel 3 Mar 31, 20240/6 normalizedLevel 3 Jun 30, 20240/7 normalizedLevel 3 Sep 30, 20240/8 normalizedLevel 3 Dec 31, 20240/8 normalizedLevel 3 Mar 31, 20250/8 normalizedLevel 3 Jun 30, 20255/8 normalizedLevel 3 Sep 30, 20256/8 normalizedLevel 3 Dec 31, 20256/8 normalizedLevel 3 Mar 31, 20267/8 normalizedLevel 3 Jun 30, 20268/8 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 181.77%
Current: 43.29%
Delta: -138.48%

Capex Intensity Increased

Previous: 0.05%
Current: 0.06%
Delta: 0.01%

Cash Generation Decreased

Previous: 18.92%
Current: 11.46%
Delta: -7.45%

Inventory Pressure Decreased

Previous: 10.12%
Current: 3.00%
Delta: -7.12%

Margin Decreased

Previous: 76.33%
Current: 73.40%
Delta: -2.93%

Profitability Decreased

Previous: 15.30%
Current: 13.85%
Delta: -1.45%

Sbc Intensity Decreased

Previous: 4.54%
Current: 4.35%
Delta: -0.19%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · PBYI Fundamental State →Has State · PUMA BIOTECHNOLOGY, INC. →Transitioned To · PBYI Fundamental State →Transitioned To · PBYI BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · PBYI CAPEX_INTENSITY_INCREASED →Transitioned To · PBYI CASH_GENERATION_DECREASED →Transitioned To · PBYI INVENTORY_PRESSURE_DECREASED →Transitioned To · PBYI MARGIN_DECREASED →Transitioned To · PBYI PROFITABILITY_DECREASED →Transitioned To · PBYI SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.